News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
579,884 Results
Type
Article (42012)
Company Profile (297)
Press Release (537575)
Section
Business (167268)
Career Advice (2408)
Deals (30276)
Drug Delivery (87)
Drug Development (78294)
Employer Resources (147)
FDA (14235)
Job Trends (12942)
News (294846)
Policy (28445)
Tag
Academia (2653)
Africa (734)
Alliances (42545)
Alzheimer's disease (1192)
Antibody-drug conjugate (ADC) (57)
Approvals (14163)
Arizona (120)
Artificial intelligence (68)
Asia (35363)
Australia (7017)
Bankruptcy (314)
Best Places to Work (10315)
Biotechnology (239)
C2C Services and Suppliers (55936)
California (1691)
Canada (860)
Cancer (414)
Career advice (2020)
Cell therapy (123)
China (126)
Clinical research (60985)
Collaboration (128)
Colorado (64)
Connecticut (62)
COVID-19 (2461)
Cystic fibrosis (74)
Data (225)
Diabetes (75)
Diagnostics (5456)
Drug pricing (67)
Earnings (59227)
Employer resources (132)
Europe (78979)
Events (85833)
Executive appointments (140)
FDA (14423)
Florida (227)
Funding (131)
Gene therapy (99)
GLP-1 (534)
Government (4132)
Healthcare (17104)
Hotbed/Location (389497)
Illinois (215)
Indiana (133)
Infectious disease (2485)
Inflammatory bowel disease (96)
Interviews (516)
IPO (13973)
Job creations (2747)
Job search strategy (1671)
Kansas (84)
Layoffs (391)
Legal (5987)
Liver cancer (55)
Lung cancer (99)
Manufacturing (75)
Maryland (355)
Massachusetts (1306)
Medical device (10849)
Medtech (10853)
Mergers & acquisitions (16161)
Metabolic disorders (250)
Michigan (113)
Minnesota (181)
Neuroscience (1338)
New Jersey (499)
New York (536)
NextGen Class of 2024 (5923)
Non-profit (4097)
North Carolina (553)
Northern California (743)
Obesity (146)
Ohio (92)
Opinion (197)
Patents (68)
Pennsylvania (485)
People (52768)
Phase I (19041)
Phase II (26935)
Phase III (20127)
Pipeline (102)
Policy (55)
Postmarket research (2374)
Preclinical (8060)
Press Release (60)
Rare diseases (134)
Real estate (4475)
Recruiting (59)
Regulatory (19223)
Research institute (2260)
Resumes & cover letters (355)
South America (1005)
Southern California (704)
Startups (3166)
Texas (202)
United States (7472)
Vaccines (437)
Washington State (225)
Weight loss (136)
Date
Today (157)
Last 7 days (620)
Last 30 days (2085)
Last 365 days (35407)
2024 (24410)
2023 (37497)
2022 (48413)
2021 (52027)
2020 (50012)
2019 (42546)
2018 (32073)
2017 (29662)
2016 (28193)
2015 (32972)
2014 (25387)
2013 (20575)
2012 (21784)
2011 (22690)
2010 (20430)
579,884 Results for "aquestive therapeutics formerly known as monosolrx".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
Aquestive Therapeutics, Inc. announced that the Aquestive management team will participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism and host investor meetings on July 9, 2024.
June 27, 2024
·
2 min read
Business
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
Aquestive Therapeutics, Inc. today announced the appointment of Abigail Jenkins to the Company’s Board of Directors, effective April 1, 2024.
April 1, 2024
·
6 min read
Business
Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities
Aquestive Therapeutics, Inc. today announced it has strengthened its leadership team with three executive appointments ahead of the anticipated launch of Anaphylm™.
June 3, 2024
·
8 min read
Deals
Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
Aquestive Therapeutics, Inc. today announced the closing of its previously announced underwritten public offering of 16,666,667 shares of its common stock at the public offering price of $4.50 per share.
March 25, 2024
·
2 min read
Pharm Country
Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual Film
Aquestive Therapeutics, Inc. today released positive topline pharmacokinetic (PK) data from the temperature / pH study of its product candidate Anaphylm™ (epinephrine) Sublingual Film.
June 25, 2024
·
10 min read
Press Releases
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
August 23, 2024
·
3 min read
Pharm Country
Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference 2024
Aquestive Therapeutics, Inc., a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, announced that the management team will participate in The Citizens JMP Life Sciences Conference on May 13, 2024.
May 9, 2024
·
3 min read
Pharm Country
Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET
Aquestive Therapeutics, Inc. today announced that it will report results for the first quarter ended March 31, 2024 and provide an update on recent developments in its business after market close on Tuesday, May 7, 2024.
April 25, 2024
·
3 min read
Pharm Country
Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024
Aquestive Therapeutics, Inc. announced its expected addition to the broad-market Russell 3000® and Russell 2000® Indexes at the conclusion of the 2024 Russell U.S. indexes annual reconstitution, effective at the open of U.S. equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24, 2024.
June 18, 2024
·
13 min read
Pharm Country
Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”) today announced a poster presentation highlighting the crossover study for the Company’s product candidate, Libervant™ (diazepam) Buccal Film for treatment of children with epilepsy aged two to five, will be presented at the 76th Annual Meeting of the American Academy of Neurology (AAN) in Denver from April 13 to 18, offering both in-person attendance and live online participation in a hybrid format.
April 12, 2024
·
7 min read
1 of 57,989
Next